DOI: http://dx.doi.org/10.18203/2349-2902.isj20205881

Role of tamsulosin in patients undergoing ESWL for renal and ureteric stones

Gyan Prakash Singh, Sabyasachi Panda, Pradeepta Kumar Panda

Abstract


Background: To determine the effect of tamsulosin, as adjunctive medical therapy on the outcome of extracorporeal shock wave lithotripsy (ESWL) for solitary renal and ureteric calculi.

Methods: From January 2017 onwards, a prospective, randomized controlled study was conducted in patients with solitary renal or ureteral calculus measuring less than 20 mm undergoing ESWL. The study group (n=62) received 0.4 mg of tamsulosin daily till stone clearance or a maximum period of 12 weeks and control group (n=58) received ESWL only. Parameters assessed were stone size, composition, location, stone clearance, mean time to clearance, analgesic requirement, steinstrasse, need for hospitalization and/or auxiliary procedures.

Results: There was no difference between the 2 groups with regards to age, stone size, location or composition. The complete clearance rate for renal stones was 62.7% and 36.5% (p=0.004) and for ureteric stone was 89.4% and 58.8% (p=0.03) in study and control groups, respectively. The control group had a higher rate of clinically insignificant residual fragments (CISF i.e. <3 mm), 12.9% versus 35.4% (p=0.002). There was no significant difference in the mean time to stone clearance (p=0.07) or in the incidence of steinstrasse formation (p=0.12). The mean analgesic requirement (p=0.01), need for auxiliary procedures and hospitalization (p=0.03) was significantly was higher in the control group.

Conclusions: Tamsulosin increase the complete clearance rate and decrease the incidence of CISF. It also reduces analgesic requirement, need of additional procedures and hospitalization rate and might be useful as a routine adjunctive therapy following ESWL.


Keywords


CISF, ESWL, Tamsulosin, Ureteric stone

Full Text:

PDF

References


Segura JW, Preminger GM, Assimos DG, Dretler SP, Kahn RI, Lingeman JE, et al Ureteral stones clinical guidelines panel summary report on the management of ureteral calculi. J Urol. 1997;158:1915.

Porpiglia F, Destefanis P, Fiori C and Fontana D. Effectiveness of nifedipine and deflazocort in the management of distal ureteral stones. Urology. 2000;56:579.

Weiss RM. Physiology and pharmacology of the renal pelvis and ureter. In: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ, eds. Campbell’s Urology, 8th edn. Sec. III. Philadelphia: W Saunders Co; 2002:377-407.

Dellabella M, Milanese G and Muzzonigro G. Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi. J Urol. 2005;174:167.

Borghi L, Meschi T, Amato F, Novarini A, Giannini A, Quarentilli C et al. Nifedipine and methylprednisolone in facilitating ureteral stone passage: a randomized, double blind placebo controlled study. J Urol. 1994;152:1095.

Hussain Z, Inman RD, Elves AW, Shipstone DP, Ghiblawi S, Coppinger SW. Use of glyceryl trinitrate patches in patients with ureteral stones: a randomized, double-blind, placebo-controlled study. Urology. 2001;58:521.

Sigala S, Dellabella M, Milanese G, Fornari S, Faccoli S, Palazzolo F, et al. Evidence for the presence of alpha1 adrenoceptor subtypes in the human ureter. Neurourol Urodyn. 2005;24:142.

Dellabella M, Milanese G, Muzzonigro G. Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones. J Urol. 2003;170:2202.

Ishigooka M, Nakada T, Hashimoto T, Iijima Y, Yaguchi H. Spinal substance P immunoreactivity is enhanced by acute chemical stimulation of the rat prostate. Urology. 2002;59:139.

Kinnman E, Nygards EB, Hansson P. Peripheral alphaadrenoreceptors are involved in the development of capsaicin induced ongoing and stimulus evoked pain in humans. Pain. 1997;69:79.

Gravina GL, Costa AM, Ronchi P, Galatioto GP, Angelucci A, Castellani D et al. Tamsulosin treatment increases clinical success rate of single extracorporeal shock wave lithotripsy of renal stones. Urology. 2005;66:24.

Porpiglia F, Destefanis P, Fiori C, Scarpa RM and Fontana D. Role of adjunctive medical therapy with nifedipine and deflazocort after shock wave lithotripsy of ureteral stones. Urology. 2002;59:835.

Resim S, Ekerbicer HC and Ciftci A. Role of tamsulosin in treatment of patients with steinstrasse developing after extracorporeal shock wave lithotripsy. Urology. 2005;66:945.

Morita T, Wada I, Saeki H, Tsuchida S, Weiss RM. Ureteral urine transport: changes in bolus volume, peristaltic frequency, intraluminal pressure and volume of flow resulting from autonomic drugs. J Urol. 1987;137:132.

Fedullo LM, Pollack HM, Banner MP, Amendola MA, Van Arsdalen KN. The development of steinstrassen after ESWL: frequency, natural history, and radiologic management. Am J Roentgenol. 1988;151:1145.

Andersson KE, Forman A. Effects of calcium channel blockers on urinary tract smooth muscle. Acta Pharmacol Toxicol. 1986;58:193.

Yilmaz E, Batislam E, Basar MM, Tuglu D, Ferhat M, Basar H. The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones. J Urol. 2005;173:2010.

O’Leary MP. Tamsulosin, current clinical experience. Urology. 2001;58:42.

Delvecchio FC, Preminger GM. Management of residual stones. Urol Clin North Am. 2000;27:347-54.

Khaitan A, Gupta NP, Hemal AK, Dogra PN, Seth A, Aron M. Post- SWL, clinically insignificant Residual Stones: Reality or Myth? Urology 2002;59:20-4.

Beck EM, Riehle RA. The fate of residual fragments after extracorporeal lithotripsy monotherapy for infection stones. J Urol. 1991;145:6-10.

Osman MM, Alfano Y, Kamp S, Haecker A, Alken P, Michel MS, et al. 5-year-follow-up of patients with clinically insignificant residual fragments after extracorporeal shockwave lithotripsy. Eur Urol. 2005;47:860-4.